Table 4. Clinical and pathological characteristics of study patients and cohorts included in survival and toxicity analyses.
| Characteristics | Total cohort (frequency) n = 196 | Survival cohort (frequency) n = 126 | Toxicity cohort (frequency) n = 57 |
|---|---|---|---|
| Gender | |||
| Male | 122 (62%) | 75 (60%) | 37 (65%) |
| Female | 74 (38%) | 51 (40%) | 20 (35%) |
| Age | |||
| < 14 years | 60 (31%) | 43 (34%) | 24 (42%) |
| ≥ 14 years | 136 (69%) | 83 (66%) | 33 (58%) |
| Site | |||
| Femur | 101 (51%) | 75 (60%) | 30 (53%) |
| Tibia | 39 (20%) | 27 (21%) | 15 (26%) |
| Humerus | 23 (12%) | 15 (12%) | 9 (16%) |
| Fibula | 8 (4%) | 5 (4%) | 3 (5%) |
| Other | 25 (13%) | 4 (3%) | 0 (0%) |
| Metastasis at diagnosis | |||
| Absent | 179 (91%) | 126 (100%) | 57 (100%) |
| Present | 17 (9%) | 0 (0%) | 0 (0%) |
| Histologic Subtype | |||
| Osteoblastic | 125 (64%) | 88 (70%) | 43 (75%) |
| Fibroblastic | 24 (12%) | 19 (15%) | 6 (11%) |
| Chondroblastic | 18 (9%) | 14 (11%) | 7 (12%) |
| Telangiectatic | 3 (2%) | 2 (2%) | 1 (2%) |
| Not specified | 22 (11%) | 3 (2%) | 0 (0%) |
| Irradiation-induced | 4 (2%) | 0 (0%) | 0 (0%) |
| Surgery | |||
| Yes | 194 (99%) | 126 (100%) | 57 (100%) |
| No | 2 (1%) | 0 (0%) | 0 (0%) |
| Treatment | |||
| Adjuvanta | 16 (8%) | 0 (0%) | 0 (0%) |
| Neo-adjuvantb | 171 (87%) | 126 (100%) | 57 (100%) |
| No chemotherapy | 9 (5%) | 0 (0%) | 0 (0%) |
a
Treatment including doxorubicin, cisplatin and methotrexate.
b
Treatment including doxorubicin, cisplatin, methotrexate and ifosfamide.